I have seen many Roth meetings for 2-3 days. Nothing abnormal about it. Doubt the buyout spec. Most likely an upgrade coming. They did come out with a statement that the teva deals adds +$10 to the stock.
Maybe consulting for license deals,as per Roth's website, they work on mergers, acquisitions and licensing opps to increase shareholder value. Could very easilty generate a few hundred million by out-licensing 50 drugs for $1-5MIL a pop to use stacatto, plus milestones and royalties.
Roth site..."We also work closely with management and the Board of Directors in evaluating acquisition opportunities, licenses and strategic partnerships to accelerate growth and enhance shareholder value. "